by Marisa Wexler, MS | Jan 23, 2026 | Myeloma News
After a year of treatment with the experimental medication atebimetinib as an add-on to chemotherapy, about two-thirds of pancreatic cancer patients in an ongoing study are still alive — nearly twice as many as would be expected to live this long with standard-of-care...
by MM360 Staff | Jan 23, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Jan 23, 2026 | Publications
Front Immunol. 2026 Jan 6;16:1744165. doi: 10.3389/fimmu.2025.1744165. eCollection 2025. ABSTRACT BACKGROUND: The efficacy of CD38 monoclonal antibody (mAb)-based quadruplet regimens versus triplet regimens in newly diagnosed multiple myeloma (NDMM) patients with...
by MM360 Staff | Jan 23, 2026 | Publications
EClinicalMedicine. 2026 Jan 8;91:103750. doi: 10.1016/j.eclinm.2025.103750. eCollection 2026 Jan. ABSTRACT BACKGROUND: Diagnostic advancements and classification updates appear to have reshaped the natural history of smoldering multiple myeloma (SMM), though this...
by MM360 Staff | Jan 23, 2026 | Publications
Front Oncol. 2026 Jan 6;15:1729177. doi: 10.3389/fonc.2025.1729177. eCollection 2025. ABSTRACT Daratumumab, a CD38-targeting monoclonal antibody, is a key component of therapy for both newly diagnosed and relapsed or refractory multiple myeloma. By depleting...
